New drug duo shows promise against aggressive colon cancer
NCT ID NCT05890742
First seen Jun 03, 2026 · Last updated Jun 12, 2026 · Updated 2 times
Summary
This study tests whether giving two immunotherapy drugs (IBI310 and sintilimab) before surgery can eliminate or shrink tumors in people with a specific genetic type of colon cancer (MSI-H/dMMR). About 453 adults with stage IIB or III colon cancer that can be surgically removed will receive the drug combination before their operation. The main goals are to see if the cancer completely disappears after treatment and to measure how long patients remain cancer-free.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MSI-H are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Sun Yat-sen University Cancer Center
Guangzhou, Guangdong, 510060, China
Conditions
Explore the condition pages connected to this study.
Conditions inferred from the trial description
These were inferred from the trial's summary, not listed by the trial registrant.